Fennec Pharmaceuticals Inc's Business Segments

The registrant develops and commercializes PEDMARK®, a sodium thiosulfate injection product. Their operations include protecting and enforcing intellectual property rights related to PEDMARK®, encompassing patents licensed from OHSU. Competitors such as CIPLA have submitted Abbreviated New Drug Applications (ANDAs) to the FDA for generic versions of PEDMARK®, including Paragraph IV Certifications challenging the validity or infringement of the registrant's patents. The registrant has entered into a settlement agreement with Cipla Limited and Cipla USA, Inc., which delays Cipla's market entry with a generic version until September 1, 2033, or earlier under specified conditions. The registrant is responsible for prosecuting and maintaining patents and may engage in litigation to defend their intellectual property, which could involve significant costs and disruptions. They acknowledge uncertainties in patent protection, including potential patent invalidation, third-party challenges, and limitations in foreign jurisdictions. Additionally, the registrant relies on trade secrets to protect certain technology but recognizes risks related to disclosure and enforcement. Their commercial success depends on obtaining and maintaining effective patent protection and defending against infringement to sustain competitive advantages for PEDMARK®.

The Company operates and manages its business within a single operating segment focused on the production and commercialization of PEDMARK. All employees support this segment exclusively.